R&D Spending Showdown: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.

R&D Spending: Amneal vs. CymaBay - A Decade of Change

__timestampAmneal Pharmaceuticals, Inc.CymaBay Therapeutics, Inc.
Wednesday, January 1, 201410673500015823000
Thursday, January 1, 201513687000017026000
Friday, January 1, 201620474700015941000
Sunday, January 1, 201719193800018938000
Monday, January 1, 201821045100058124000
Tuesday, January 1, 201920228700083837000
Wednesday, January 1, 202019058500035882000
Friday, January 1, 202120956300064542000
Saturday, January 1, 202220004600067995000
Sunday, January 1, 202316777800080118000
Loading chart...

Unveiling the hidden dimensions of data

R&D Spending Trends: A Tale of Two Companies

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of innovation and future growth. Over the past decade, Amneal Pharmaceuticals, Inc. and CymaBay Therapeutics, Inc. have shown contrasting trends in their R&D investments. From 2014 to 2023, Amneal's R&D expenses have fluctuated, peaking in 2018 with a 97% increase from 2014, before declining by 20% in 2023. In contrast, CymaBay's R&D spending has seen a more consistent upward trajectory, with a remarkable 406% increase from 2014 to 2023. This divergence highlights Amneal's strategic shifts and CymaBay's commitment to innovation. As the pharmaceutical landscape evolves, these spending patterns may offer insights into each company's future market positioning and potential breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025